SOPH Q4 2025 Earnings Call Summary

SOPHiA GENETICS S.A. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

Q4 2025 Revenue: $21.7 million, up 22% from $17.7 million in Q4 2024.
Full Year 2025 Revenue: $77.3 million, representing 19% year-over-year growth.
Platform Analysis Volume: Over 105,000 in Q4, a 16% increase year-over-year; total for 2025 was 391,000.
Gross Profit: $14.7 million in Q4, up 21% from $12.1 million; full-year gross profit was $52.1 million.
Gross Margin: 67.7% in Q4, slightly down from 68.2% in Q4 2024; full-year gross margin was 67.4%.
Operating Loss: $18.5 million in Q4, compared to $17.4 million in the prior year; full-year operating loss was $70.9 million.
Adjusted EBITDA Loss: $9.9 million in Q4, worsening from $9.1 million; full-year adjusted EBITDA loss was $41.5 million.
Cash Position: $70.3 million as of December 31, 2025, excluding recent $14.4 million raised in Q1 2026.

2. Strategic Updates and Business Highlights

Customer Growth: Signed 124 new customers in 2025, with a record 30 in Q4; average contract value increased by 120% year-over-year.
Platform Enhancements: Launched a new generation of SOPHiA DDM, improving data processing capacity by 10 times and reducing analysis time for whole genomes to under 6 hours.
Customer Satisfaction: Net promoter score of 67 and customer satisfaction score over 97% with annualized revenue churn below 1%.
New Initiatives: Introduced SOPHiA DDM Digital Twins for personalized treatment simulations and announced a partnership with MD Anderson for co-development of a whole transcriptome test.

3. Forward Guidance and Outlook

2026 Revenue Guidance: Expected to be between $92 million and $94 million, indicating 20%-22% growth.
Adjusted EBITDA Loss Guidance: Projected to be between $29 million and $32 million, an improvement from 2025.
Growth Drivers: Anticipated contributions from MSK-ACCESS, biopharma partnerships, and increasing analysis volumes, particularly in the U.S. and liquid biopsy markets.

4. Bad News, Challenges, or Points of Concern

Operating Losses: Continued significant operating losses and cash burn, although improved from previous years.
Foreign Exchange Impact: Adverse effects from the strengthening Swiss franc, increasing operational costs when reported in USD.
Litigation Costs: Ongoing legal expenses related to patent infringement claims by Guardant Health, impacting financials.
Competitive Pressures: Increased competition in the U.S. market, particularly from send-out labs ramping up their commercial efforts.

5. Notable Q&A Insights

Growth Drivers: Management emphasized the ramp-up of MSK-ACCESS and other high ASP products as key growth contributors for 2026.
Net Dollar Retention: Increased to 115%, attributed to effective cross-selling and customer stickiness.
Pharma Partnerships: While there is optimism for biopharma contributions, management noted that revenue from these contracts will take time to ramp up.
Implementation Timelines: Improved efficiency in customer onboarding, with a focus on reducing time to revenue, but still a work in progress.
Sales Strategy: Plans to expand U.S. sales operations to capitalize on growth opportunities, with a focus on maintaining operational efficiency.

Overall, SOPHiA GENETICS S.A. demonstrated strong growth in customer acquisition and revenue, alongside strategic advancements in their platform. However, challenges remain in terms of profitability, competitive pressures, and external litigation.

SOPH — SOPHiA GENETICS S.A.